在质瘤患者中使用TTFields的现实世界经验,重点是治疗使用疗法
Claudius Jelgersma1, Joan Alsolivany1, Gülsüm Akkas1
1Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Frontiers in oncology
|January 22, 2025
概括
现实数据显示,高度质瘤患者中瘤治疗场 (TTFields) 的使用率平均为65.5%,低于推的75%. 在瘤复发后,坚持显著下降,突出需要改进监测和战略,以提高长期患者的遵守.
科学领域:
- 神经瘤学神经瘤学
- 医学物理 医学物理
- 临床试验 临床试验
背景情况:
- 瘤治疗场 (TTFields) 是一种成熟的高级质瘤辅助疗法,在EF-14试验中被证明是有效的.
- 最佳的患者结果与每天超过18小时的TTFields使用 (75%的使用) 相关,附加效益显示的附加效益较高 (90%).
- 鉴于其成本和患者报告的约束因素,评估TTFields的合规性至关重要.
研究的目的:
- 为了回顾分析现实世界的TTFields使用模式在一个高体积的学术中心.
- 识别影响TTFields坚持的因素,并评估随时间推移和与瘤复发相关的使用趋势.
主要方法:
- 在2015年6月至2022年2月期间,对113名高度质瘤患者进行了TTFields治疗的回顾性分析.
- 排除在2个月内使用<50%的患者;分析治疗持续时间,休息日和平均使用百分比.
- 线性回归以确定使用的预测因素;评估瘤复发前后的使用趋势.
主要成果:
- 平均TTFields的使用率为65.5% (SD 17.6%),在前3个月 (71.6%-77.7%) 的遵守率最高.
- 没有发现使用的显著预测因素 (年龄,性别,时间,持续时间).
- 在瘤复发诊断后,使用率大幅下降至52.3%,尽管在沟通之前一直坚持.
结论:
- 现实世界TTFields在高度质瘤患者的使用往往低于推的75%门.
- 瘤复发与TTFields坚持显著下降有关.
- 改善治疗启动及时性和长期坚持的策略对于最大限度地发挥TTFields的益处至关重要.
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.